Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siIFIT3-2
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal, Transfection
01
Overview
siIFIT3-2 is a specific small interfering RNA (siRNA) sequence designed to target and silence the expression of the IFIT3 (Interferon-induced protein with tetratricopeptide repeat 3) gene. IFIT3 is a member of the IFIT family known for its roles in antiviral immunity and cellular regulation. In the context of ulcerative colitis (UC), IFIT3 expression is upregulated and contributes to the inflammatory response. siIFIT3-2 works by degrading IFIT3 mRNA, which in turn inhibits the STAT1/2 signaling pathway and shifts macrophage polarization from the pro-inflammatory M1 phenotype toward a more regulatory state. This experimental RNA therapy is being investigated for its potential to relieve the symptoms and underlying inflammation associated with ulcerative colitis.
- Other names
- IFIT3 siRNAIFIT-3 siRNAIFIT 3 siRNAsi-IFIT3-2si-IFIT-3-2si-IFIT 3-2
02
Targets
IFIT3 (Interferon-induced protein with tetratricopeptide repeat 3)
Beyond the preview
Go deeper on siIFIT3-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siIFIT3-2.